Development of a Marburg self-amplifying mRNA-lipid nanoparticle vaccine: Differential effects when co-formulated with Toll Receptor Agonists

Authors

• Allan Watkinson, Labcorp, United Kingdom
• Gillian Hoover, Antibody Reagents & Vaccines, LabcorpFollow
• Anas Tomeh, BioCMC, Labcorp
• Sarah Horst, Antibody Reagents & Vaccines, Labcorp
• Erik de Leeuw, Antibody Reagents & Vaccines, Labcorp
• Murty Chengalvala, Antibody Reagents & Vaccines, Labcorp

Conference Dates

May 19 - 24, 2024

Abstract

Please click Additional Files below to see the full abstract.

Recommended Citation

Allan Watkinson, Gillian Hoover, Anas Tomeh, Sarah Horst, Erik de Leeuw, and Murty Chengalvala, "Development of a Marburg self-amplifying mRNA-lipid nanoparticle vaccine: Differential effects when co-formulated with Toll Receptor Agonists" in "Vaccine Technology IX", Linda Lua, The University of Queensland, Australia; Charles Lutsch, Sanofi-Vaccines, France; Francesc Gòdia, Universitat Autònoma de Barcelona (UAB), Spain; Tara Tagmyer, CMC Leader, USA Eds, ECI Symposium Series, (2024). https://dc.engconfintl.org/vaccine_ix/44